The Indianapolis-based company said it had net income of $1.81 per share. Earnings, adjusted for one-time gains and costs, came to $3.84 per share. The results beat Wall Street expectations. The average estimate of 17 analysts surveyed by Zacks Investment Research was for earnings of $3.80 per share.

Elevance Health released fourth-quarter earnings that topped analyst expectations, sending its stock higher in pre-market trading Thursday. Shares of Elevance gained more than 4% to $408 a share before the bell.

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting."

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a high estimate of $512.00 and a low estimate of $478.00. A decline of 6.69% from the prior average price target is evident in the current average.

Elevance executives talked about the cost trend environment for employer health plans Thursday, during a conference call with securities analysts. The Indianapolis-based health insurer and health ...

Elevance Health Inc.’s stock jumped 5% in premarket trade Thursday and boosted other health insurance stocks, after the company delivered better-than-expected earnings and forecast growth for 2025, easing investor concerns after a big miss in the third quarter.

In a call with investors, CEO Gail Boudreaux didn’t directly address the killing of UnitedHealthcare’s top executive but spent more time than usual arguing Elevance is working to improve healthcare.

Elevance Health Inc.'s stock rose 2% Thursday and ... Medicaid business following the recent re-eligibility checks." The Indianapolis-based company (ELV) had net income of $413 million, or $1 ...

Elevance Health's board has raised the health insurer and healthcare-services provider's quarterly dividend by 4.9%, to $1.71 from $1.63. The new payout, equal to $6.84 a year, represents an annual yield of about 1.75%, based on Wednesday's closing price of $390.73, up from 1.67%.

Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target